QUASAR results: The prognostic validity of a colon cancer recurrence score and the role of multigene profiles in determining risk

Current Colorectal Cancer Reports

Volumn 6, Issue 3, 2010, Pages 144-147

  Rasul, Kakil Ibrahim ^b   Kerr, David J ^a  

^a SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Colorectal gene signature; Prognosis; QUASAR; Stage II recurrence score

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; GENE EXPRESSION PROFILING; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; RECTUM CANCER; RECURRENCE RISK; REVIEW; VALIDATION STUDY;

EID: 79952738224     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-010-0053-2     Document Type: Review

References (17)

1. Gray R, Barnwell J, McConkey C, et al.: QUASAR: a randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients. QUASAR Collaborative Group. Lancet 2007, 370(9604):2020-2029.
2. Bell SM, Scott N, Cross D, et al.: Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993, 104:57-64. (Pubitemid 23040006)
3. Benhattar J, Losi L, Chaubert P, et al.: Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993, 104:1044-1048. (Pubitemid 23090756)
4. Goh HS, Yao J, Smith DR: p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995, 55:5217-5221.
5. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al.: Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998, 16:427-433. (Pubitemid 28135583)
6. Lanza G, Matteuzzi M, Gafa R, et al.: Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998, 79:390-395. (Pubitemid 28359738)
7. Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196-1206. (Pubitemid 32319494)
8. Laurent-Puig P, Olschwang S, Delattre O, et al.: Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992, 102:1136-1141.
9. Jen J, Kim H, Piantadosi S, et al.: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994, 331:213-221. (Pubitemid 24226678)
10. Diep CB, Thorstensen L, Meling GI, et al.: Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 2003, 21:820-829. (Pubitemid 46606441)
11. Cohn KH, Ornstein DL, Wang F, et al.: The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study. Cancer 1997, 79:233-244. (Pubitemid 27029887)
12. Van't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
13. Beer DG, Kardia SLR, Huang C, et al.: Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
14. Shipp MA, Ross KN, Tamayo P, et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8:68-74. (Pubitemid 34101731)
15. Wang Y, Jatkoe T, Zhang Y, et al.: Gene expression profiles and molecular markers to predict recurrence of Dukes B colon cancer. J Clin Oncol 2004, 27:1564-1571. Along with the articles by Barrier et al. [16•] and Kerr et al. [17•], this report provides the most recent information on the gene expression profiles and molecular markers for predicting stage II colon cancer prognosis.
16. Barrier A, Boelle PY, Roser F et al.: Stage II colon cancer prognosis prediction by tumour gene expression profiling. J Clin Oncol 2006, 24:4685-4691. Along with the articles by Wang et al. [15•] and Kerr et al. [17•], this report provides the most recent information on the gene expression profiles and molecular markers for predicting stage II colon cancer prognosis.
17. Kerr D, Gray R, Quirke P, et al.: A quantitative multigene RTPCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009, 27(15s):4000. Along with the articles by Wang et al. [15•] and Barrier et al. [16•], this abstract provides the most recent information on the gene expression profiles and molecular markers for predicting stage II colon cancer prognosis. QUASAR was an independent prospective validation study.